| Dragon Boat Festival an overwhelming success
With the generous contributions from paddlers and pledge donors, the third Annual Dragon Flies' Dragon Boat Festival held last Saturday Port Perry was an outstanding success.
The unofficial pledge donation total was more than $125,300 - an increase of nearly $20,000 from last year - with proceeds supporting breast cancer awareness programs and early diagnosis and treatment at Ross Memorial Hospital, Lakeridge Health in Port Perry, Uxbridge Cottage Hospital and the Durham Regional Cancer Centre in Oshawa. The uniqueness of this fundraising event is that all monies will remain in the local areas of Durham Region and City of Kawartha Lakes. .
Is Health Care Making You Better—or Dead?
Professor Regina Herzlinger has been studying the U.S. health care system for decades, advocating for consumer-driven reform as the best remedy. But the slow pace of change, which she attributes to a fat-cat network of insurers, policymakers, hospitals, and even employers, has her fed up. Her new book, Who Killed Health Care? adopts the emotional language of a manifesto in demanding change to make health care more responsive to customers, affordable to those in need, and a hotbed of innovation and entrepreneurship. Key concepts include: Today's American health care system is set up structurally to reward the major players—hospitals, health insurers, and lawmakers—while short-changing patients and taxpayers. Health care is not the hotbed of innovation and entrepreneurial activity one might expect from a $2 trillion industry.
Maxygen Initiates Phase IIa Clinical Trial of MAXY-G34 in Breast ...
REDWOOD CITY, Calif., July 2 /PRNewswire-FirstCall/ -- Maxygen, Inc. today announced that it has initiated a phase IIa trial to evaluate the efficacy, safety and tolerability of MAXY-G34 in the treatment of chemotherapy-induced neutropenia. MAXY-G34 is a novel pegylated granulocyte colony stimulating factor (PEG-GCSF) shown in preclinical and Phase I studies to have novel and potentially superior properties compared to the current PEG- GCSF therapy. "Patients and physicians have limited options for treatment of neutropenia," said Russell Howard, chief executive officer of Maxygen. "With MAXY-G34, we hope to expand those options and improve the outcome for many chemotherapy patients. During this first Phase II trial we will begin to learn more about how our drug might play a role in the large, undifferentiated GCSF market." The Phase IIa trial, which will be conducted at multiple centers in Eastern Europe, is the first trial of MAXY-G34 in patients.
|
